{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=11", "query": { "intervention": "Prednisone", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1199, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:54:53.191Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04569032", "title": "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2020-11-12", "completion_date": "2026-01-12", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04569032" }, { "nct_id": "NCT07190300", "title": "TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Tulmimetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 181, "start_date": "2026-01-13", "completion_date": "2032-08-02", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190300" }, { "nct_id": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Chronic Lymphocytic Lymphoma", "B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "CT Scan chest/abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "18-FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-12-16", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599634" }, { "nct_id": "NCT04729114", "title": "A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Metastatic Castration Resistant Prostate Cancer", "Metastatic Castration-sensitive Prostate Cancer" ], "interventions": [ { "name": "PRL-02 injection", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 174, "start_date": "2021-06-14", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 24, "location_summary": "Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729114" }, { "nct_id": "NCT02043678", "title": "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Matching placebo (normal saline)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 806, "start_date": "2014-03-30", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043678" }, { "nct_id": "NCT01995058", "title": "Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Castration Resistant Prostate Cancer", "Prostatic Neoplasms" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "abiraterone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2014-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oxnard", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995058" }, { "nct_id": "NCT05689021", "title": "CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate/Niraparib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2024-03-05", "completion_date": "2026-07-02", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05689021" }, { "nct_id": "NCT00058084", "title": "Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 80, "start_date": "2003-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058084" }, { "nct_id": "NCT02029638", "title": "BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "bone marrow transplant", "type": "BIOLOGICAL" }, { "name": "MESNA", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2014-01-07", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029638" }, { "nct_id": "NCT00424749", "title": "Rituxan in Churg Strauss Syndrome With Renal Involvement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Churg-Strauss Syndrome" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fernando Fervenza", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2007-06", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2011-12-08", "last_synced_at": "2026-10-26T07:54:53.191Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424749" } ] }